Effect of Adjuvant Mitomycin-C on Recurrent Rhegmatogenous Retinal Detachment With Proliferative Vitreoretinopathy Managed by Relaxing Retinotomy and Retinectomy.

To evaluate the role of adjuvant mitomycin-C (MMC) use in cases of recurrent rhegmatogenous retinal detachment (RRD) complicated by proliferative vitreoretinopathy (PVR) managed by relaxing retinotomy and retinectomy (RR). A retrospective analysis of consecutive patients undergoing vitreoretinal surgery with RR for RD and PVR was conducted. Patients were divided into two groups: those receiving 20 μg/0.1 mL MMC via the MMC sandwich method (Group 1) and those who did not (Group 2).Demographics, surgical characteristics, visual outcomes, and complications that may related to MMC were analysed. A total of 28 patients (14 eyes per group) were included in the study. Differences in baseline variables between groups were not significant ( > 0.05). The mean follow-up was 15.2 ± 12.2 months. In Group 1, mean preoperative best-corrected visual acuity (BCVA) improved from 2.72 ± 0.70 logMAR to 1.59 ± 0.61 logMAR postoperatively (=0.001). In Group 2, mean preoperative BCVA increased from 2.06 ± 0.80 logMAR to 1.77 ± 0.94 logMAR (=0.261). Re-surgery rates were significantly lower in Group 1 (21.4%) than in Group 2 (92.8%, =0.001). Final retinal attachment was achieved in 100% of eyes in both groups. Postoperative mean intraocular pressure (IOP) was 16.29 ± 4.46 mmHg in Group 1 and 13.92 ± 1.44 mmHg in Group 2 (=0.081). No MMC-related toxicity was observed clinically. MMC, applied via the sandwich technique, appears safe and is associated with high anatomical and functional success rates while reducing re-operations.